Ask OpenScientist

Ask a research question about Cytomegalovirus Retinitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Mappings
4
Pathophys.
8
Phenotypes
11
Pathograph
6
Medical Actions
🔗

Mappings

MONDO
MONDO:0000878 cytomegalovirus retinitis
skos:exactMatch MONDO
MONDO provides an exact disease term for cytomegalovirus retinitis.
NCIT
NCIT:C50521 Cytomegaloviral Retinitis
skos:exactMatch NCIT
NCIT provides an exact term for cytomegalovirus retinitis; cross-referenced from MONDO:0000878.
NCIT
NCIT:C50521 Cytomegaloviral Retinitis
skos:exactMatch NCIT
NCIT provides an exact term for cytomegalovirus retinitis; cross-referenced from MONDO:0000878.

Pathophysiology

4
CMV reactivation under impaired cellular immunity
In hosts with deficient CD4+ T-cell-mediated immunity (advanced HIV/AIDS, transplant recipients, or other iatrogenic immunosuppression), latent cytomegalovirus escapes immune control and resumes active replication. Loss of protective cellular immunity is the proximal permissive event for end-organ CMV disease.
CD4-positive T cell CL:0000624 ↓ DECREASED
adaptive immune response GO:0002250 ↓ DECREASED viral genome replication GO:0019079 ↑ INCREASED
Show evidence (1 reference)
PMID:11294581 SUPPORT Human Clinical
"An important proportion of immunodepressed patients are latent carriers of the virus, and under these conditions, the lack of cellular immunity predisposes the patient to an active infection in which the virus is replicating."
Directly links loss of cellular immunity to reactivation and active CMV replication.
Productive CMV infection of the retina
Replicating cytomegalovirus reaches the eye and productively infects retinal cells. In profoundly immunosuppressed HIV-positive patients, the retina is one of the most characteristic sites of CMV end-organ disease.
retinal pigment epithelial cell CL:0002586 photoreceptor cell CL:0000210
viral process GO:0016032 ↑ INCREASED
Show evidence (1 reference)
PMID:11294581 SUPPORT Human Clinical
"In HIV-positive patients, CMVD tends to manifest itself as retinitis and involvement of the gastrointestinal tract."
Supports the retina as a principal site of CMV end-organ disease in HIV-positive patients.
Full-thickness necrotizing retinitis
Productive retinal CMV infection produces a progressive, full-thickness necrotizing retinitis with characteristic yellow-white retinal opacification and associated hemorrhage. Untreated, it advances centrifugally and can rapidly destroy the retina, leading to blindness.
cell death GO:0008219 ↑ INCREASED inflammatory response GO:0006954 ↑ INCREASED
Show evidence (1 reference)
PMID:12768225 SUPPORT Human Clinical
"Cytomegalovirus (CMV) retinitis can rapidly lead to blindness in patients with acquired immune deficiency syndrome (AIDS)."
Supports rapid progression of CMV retinitis to blindness in AIDS.
Immune recovery uveitis
When cellular immunity is restored, most often after initiation of antiretroviral therapy in HIV/AIDS, a paradoxical intraocular inflammatory reaction can develop in eyes with prior CMV retinitis. This immune recovery uveitis is an important cause of visual morbidity despite control of the underlying viral infection.
adaptive immune response GO:0002250 ↑ INCREASED inflammatory response GO:0006954 ↑ INCREASED
Show evidence (1 reference)
PMID:39046420 SUPPORT Human Clinical
"It is a paradoxical reaction that is frequently associated with a prior cytomegalovirus retinitis infection."
Supports immune recovery uveitis as a paradoxical inflammatory sequela of prior CMV retinitis.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Cytomegalovirus Retinitis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

8
Eye 5
Visual impairment Visual impairment HP:0000505
Vitreous floaters Vitreous floaters HP:0100832
Retinal detachment Retinal detachment HP:0000541
Blindness Blindness HP:0000618
Show evidence (1 reference)
PMID:12768225 SUPPORT Human Clinical
"Cytomegalovirus (CMV) retinitis can rapidly lead to blindness in patients with acquired immune deficiency syndrome (AIDS)."
Supports blindness as the major outcome of untreated CMV retinitis.
Immune recovery uveitis Uveitis HP:0000554
Show evidence (1 reference)
PMID:39046420 SUPPORT Human Clinical
"Immune recovery uveitis is an important cause of visual morbidity particularly in HIV/AIDS patients receiving highly active antiretroviral."
Supports uveitis (immune recovery uveitis) as a cause of visual morbidity after antiretroviral therapy.
Other 3
Retinitis Retinitis HP:0032118
Show evidence (1 reference)
PMID:11294581 SUPPORT Human Clinical
"In HIV-positive patients, CMVD tends to manifest itself as retinitis and involvement of the gastrointestinal tract."
Supports retinitis as the characteristic ocular manifestation of CMV in HIV-positive patients.
Yellow-white retinal lesions Yellow/white retinal lesion HP:0030506
Scotoma Scotoma HP:0000575
💊

Medical Actions

6
Fomivirsen
Action: Pharmacotherapy NCIT:C15986
Agent: fomivirsen NCIT:C174902
Fomivirsen (Vitravene) is an intravitreally administered antisense oligonucleotide complementary to cytomegalovirus immediate-early region 2 (IE2) mRNA. Approved by the FDA in 1998, it was the first antisense oligonucleotide drug ever approved and was used for CMV retinitis in AIDS patients, including relapsed disease unresponsive to conventional antivirals.
Mechanism Target:
INHIBITS Productive CMV infection of the retina — Antisense knockdown of CMV immediate-early region 2 (IE2) mRNA suppresses viral immediate-early gene expression, blocking productive replication of cytomegalovirus in the retina.
Target Phenotypes: Retinitis HP:0032118
Show evidence (3 references)
PMID:12768225 SUPPORT Human Clinical
"Fomivirsen is a novel antisense drug with a 21-nucleotide sequence complementary to the immediate early region 2 of CMV messenger ribonucleic acid."
Establishes fomivirsen's antisense mechanism targeting CMV IE2 mRNA.
PMID:12768225 SUPPORT Human Clinical
"In clinical trials, fomivirsen was shown to provide effective treatment for newly diagnosed, peripheral CMV retinitis in patients with AIDS and in those with relapsed CMV retinitis that is unresponsive to conventional therapy."
Supports clinical efficacy of fomivirsen for newly diagnosed and relapsed CMV retinitis.
PMID:38914784 SUPPORT Other
"fomiversen (for opportunistic cytomegalovirus infection)"
Lists fomivirsen among FDA-approved antisense oligonucleotide drugs, for opportunistic CMV infection.
Intravitreal ganciclovir
Action: antiviral agent therapy Ontology label: Antiviral Therapy NCIT:C16119
Agent: ganciclovir CHEBI:465284
Intravitreal ganciclovir delivers high local antiviral drug concentrations to control CMV retinitis, used alone or combined with systemic antiviral therapy.
Mechanism Target:
INHIBITS Productive CMV infection of the retina — Ganciclovir inhibits CMV DNA polymerase, suppressing productive viral replication in the retina; intravitreal delivery achieves high local antiviral concentrations.
Target Phenotypes: Retinitis HP:0032118
Show evidence (1 reference)
PMID:37452370 SUPPORT Human Clinical
"To compare the efficacy and injection frequency of intravitreal low-dose vs. intermediate-dose ganciclovir therapy in acquired immune deficiency syndrome (AIDS) patients exhibiting cytomegalovirus retinitis (CMVR)."
Supports intravitreal ganciclovir as a treatment for CMV retinitis in AIDS patients.
Oral valganciclovir
Action: antiviral agent therapy Ontology label: Antiviral Therapy NCIT:C16119
Agent: valganciclovir CHEBI:63635
Oral valganciclovir is a prodrug of ganciclovir providing systemic anti-CMV therapy for induction and maintenance treatment of CMV retinitis.
Mechanism Target:
INHIBITS Productive CMV infection of the retina — Valganciclovir is an oral prodrug of ganciclovir that provides systemic inhibition of CMV DNA polymerase, suppressing productive viral replication for induction and maintenance therapy.
Target Phenotypes: Retinitis HP:0032118
Show evidence (1 reference)
NCIT:C2629 SUPPORT Other
"Valganciclovir | Accepted_Therapeutic_Use_For | - | - | Cytomegalovirus retinitis"
NCI Thesaurus asserts accepted therapeutic use of valganciclovir for cytomegalovirus retinitis.
Foscarnet
Action: antiviral agent therapy Ontology label: Antiviral Therapy NCIT:C16119
Agent: foscarnet NCIT:C71630
Foscarnet is a pyrophosphate analogue antiviral used for CMV retinitis, particularly in ganciclovir-resistant disease or when ganciclovir is not tolerated.
Mechanism Target:
INHIBITS Productive CMV infection of the retina — Foscarnet, a pyrophosphate analogue, directly inhibits the CMV DNA polymerase pyrophosphate-binding site, suppressing productive viral replication including in ganciclovir-resistant disease.
Target Phenotypes: Retinitis HP:0032118
Antiretroviral therapy for immune reconstitution
Action: antiretroviral therapy Ontology label: Antiretroviral Therapy NCIT:C94631
In HIV/AIDS-associated CMV retinitis, antiretroviral therapy restores CD4+ T-cell-mediated immunity and is essential for durable control of the underlying opportunistic infection, though it can precipitate immune recovery uveitis.
Mechanism Target:
RESTORES CMV reactivation under impaired cellular immunity — Antiretroviral therapy restores CD4+ T-cell-mediated immunity, reversing the immunodeficiency that permits latent cytomegalovirus to reactivate and cause end-organ retinal disease.
Show evidence (1 reference)
PMID:39046420 SUPPORT Human Clinical
"Immune recovery uveitis is an important cause of visual morbidity particularly in HIV/AIDS patients receiving highly active antiretroviral."
Supports antiretroviral therapy as the immune-reconstituting treatment context for HIV/AIDS CMV retinitis.
Cidofovir
Action: antiviral agent therapy Ontology label: Antiviral Therapy NCIT:C16119
Agent: cidofovir NCIT:C1600
Cidofovir (Vistide) is an intravenous nucleotide analogue antiviral approved by the FDA for CMV retinitis in AIDS patients, particularly for relapsing or ganciclovir-resistant disease. Its prolonged intracellular half-life allows biweekly maintenance dosing. Must be co-administered with oral probenecid and intravenous saline hydration to minimize nephrotoxicity.
Mechanism Target:
INHIBITS Productive CMV infection of the retina — Cidofovir, a nucleotide analogue, inhibits CMV DNA polymerase and suppresses productive viral replication; its prolonged intracellular half-life supports biweekly maintenance dosing.
Target Phenotypes: Retinitis HP:0032118
Show evidence (1 reference)
PMID:9036797 SUPPORT Human Clinical
"Cidofovir was efficacious in delaying progression of previously untreated CMV retinitis."
Randomized controlled trial demonstrating cidofovir efficacy for previously untreated peripheral CMV retinitis in AIDS patients.
{ }

Source YAML

click to show
name: Cytomegalovirus Retinitis
creation_date: '2026-05-30T12:00:00Z'
description: >-
  Cytomegalovirus (CMV) retinitis is a sight-threatening opportunistic infection
  of the retina caused by reactivation of latent cytomegalovirus in
  immunocompromised hosts, most classically people with advanced HIV/AIDS and
  low CD4 counts, as well as transplant and immunosuppressed patients. Productive
  CMV infection produces a progressive, full-thickness necrotizing retinitis that
  can rapidly lead to retinal detachment and irreversible blindness if untreated.
  It is historically notable as the indication for fomivirsen, the first antisense
  oligonucleotide drug ever approved by the FDA (1998).
category: Infectious Disease
disease_term:
  preferred_term: cytomegalovirus retinitis
  term:
    id: MONDO:0000878
    label: cytomegalovirus retinitis
parents:
- Cytomegalovirus infection
- Viral eye infection
- Opportunistic infection
infectious_agent:
- name: Human cytomegalovirus
  description: >-
    Human cytomegalovirus (HCMV, human betaherpesvirus 5) is a ubiquitous
    betaherpesvirus that establishes lifelong latency after primary infection and
    reactivates to cause end-organ disease, including retinitis, when host cellular
    immunity is impaired.
  evidence:
  - reference: PMID:11294581
    reference_title: Laboratory diagnosis of cytomegalovirus (CMV) infections in immunodepressed patients, mainly in patients with AIDS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An important proportion of immunodepressed patients are latent carriers of
      the virus, and under these conditions, the lack of cellular immunity
      predisposes the patient to an active infection in which the virus is
      replicating.
    explanation: Establishes that CMV persists latently and reactivates to active replication when cellular immunity is lost.
pathophysiology:
- name: CMV reactivation under impaired cellular immunity
  description: >-
    In hosts with deficient CD4+ T-cell-mediated immunity (advanced HIV/AIDS,
    transplant recipients, or other iatrogenic immunosuppression), latent
    cytomegalovirus escapes immune control and resumes active replication. Loss of
    protective cellular immunity is the proximal permissive event for end-organ CMV
    disease.
  downstream:
  - target: Productive CMV infection of the retina
    description: Reactivated, replicating virus disseminates and seeds the retina.
  cell_types:
  - preferred_term: CD4-positive T cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
    modifier: DECREASED
  biological_processes:
  - preferred_term: adaptive immune response
    modifier: DECREASED
    term:
      id: GO:0002250
      label: adaptive immune response
  - preferred_term: viral genome replication
    modifier: INCREASED
    term:
      id: GO:0019079
      label: viral genome replication
  evidence:
  - reference: PMID:11294581
    reference_title: Laboratory diagnosis of cytomegalovirus (CMV) infections in immunodepressed patients, mainly in patients with AIDS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An important proportion of immunodepressed patients are latent carriers of
      the virus, and under these conditions, the lack of cellular immunity
      predisposes the patient to an active infection in which the virus is
      replicating.
    explanation: Directly links loss of cellular immunity to reactivation and active CMV replication.
- name: Productive CMV infection of the retina
  description: >-
    Replicating cytomegalovirus reaches the eye and productively infects retinal
    cells. In profoundly immunosuppressed HIV-positive patients, the retina is one
    of the most characteristic sites of CMV end-organ disease.
  downstream:
  - target: Full-thickness necrotizing retinitis
    description: Cytopathic viral infection drives inflammation and retinal cell destruction.
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  biological_processes:
  - preferred_term: viral process
    modifier: INCREASED
    term:
      id: GO:0016032
      label: viral process
  evidence:
  - reference: PMID:11294581
    reference_title: Laboratory diagnosis of cytomegalovirus (CMV) infections in immunodepressed patients, mainly in patients with AIDS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In HIV-positive patients, CMVD tends to manifest itself as retinitis and
      involvement of the gastrointestinal tract.
    explanation: Supports the retina as a principal site of CMV end-organ disease in HIV-positive patients.
- name: Full-thickness necrotizing retinitis
  description: >-
    Productive retinal CMV infection produces a progressive, full-thickness
    necrotizing retinitis with characteristic yellow-white retinal opacification
    and associated hemorrhage. Untreated, it advances centrifugally and can rapidly
    destroy the retina, leading to blindness.
  downstream:
  - target: Immune recovery uveitis
    description: Restoration of immunity in a retina bearing prior CMV antigen can trigger paradoxical intraocular inflammation.
  biological_processes:
  - preferred_term: cell death
    modifier: INCREASED
    term:
      id: GO:0008219
      label: cell death
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:12768225
    reference_title: Fomivirsen.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cytomegalovirus (CMV) retinitis can rapidly lead to blindness in patients
      with acquired immune deficiency syndrome (AIDS).
    explanation: Supports rapid progression of CMV retinitis to blindness in AIDS.
- name: Immune recovery uveitis
  description: >-
    When cellular immunity is restored, most often after initiation of
    antiretroviral therapy in HIV/AIDS, a paradoxical intraocular inflammatory
    reaction can develop in eyes with prior CMV retinitis. This immune recovery
    uveitis is an important cause of visual morbidity despite control of the
    underlying viral infection.
  biological_processes:
  - preferred_term: adaptive immune response
    modifier: INCREASED
    term:
      id: GO:0002250
      label: adaptive immune response
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:39046420
    reference_title: "Immune recovery uveitis: an ocular manifestation in HIV/AIDS receiving treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is a paradoxical reaction that is frequently associated with a prior
      cytomegalovirus retinitis infection.
    explanation: Supports immune recovery uveitis as a paradoxical inflammatory sequela of prior CMV retinitis.
phenotypes:
- category: Ophthalmological
  name: Retinitis
  description: Necrotizing inflammation of the retina is the defining feature of the disease.
  phenotype_term:
    preferred_term: Retinitis
    term:
      id: HP:0032118
      label: Retinitis
  evidence:
  - reference: PMID:11294581
    reference_title: Laboratory diagnosis of cytomegalovirus (CMV) infections in immunodepressed patients, mainly in patients with AIDS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In HIV-positive patients, CMVD tends to manifest itself as retinitis and
      involvement of the gastrointestinal tract.
    explanation: Supports retinitis as the characteristic ocular manifestation of CMV in HIV-positive patients.
- category: Ophthalmological
  name: Yellow-white retinal lesions
  description: >-
    CMV retinitis classically appears as yellow-white areas of retinal necrosis,
    often with associated retinal hemorrhage, spreading along the vascular arcades.
  phenotype_term:
    preferred_term: Yellow-white retinal lesions
    term:
      id: HP:0030506
      label: Yellow/white retinal lesion
- category: Ophthalmological
  name: Visual impairment
  description: Retinal destruction reduces visual acuity, which often does not fully recover even with treatment.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
- category: Ophthalmological
  name: Vitreous floaters
  description: Floaters are a common presenting symptom reflecting vitreous inflammatory debris.
  phenotype_term:
    preferred_term: Vitreous floaters
    term:
      id: HP:0100832
      label: Vitreous floaters
- category: Ophthalmological
  name: Scotoma
  description: Areas of retinal necrosis produce corresponding visual field defects.
  phenotype_term:
    preferred_term: Scotoma
    term:
      id: HP:0000575
      label: Scotoma
- category: Ophthalmological
  name: Retinal detachment
  description: >-
    Necrotic, atrophic retina is prone to breaks, and rhegmatogenous retinal
    detachment is a major sight-threatening late complication of CMV retinitis.
  phenotype_term:
    preferred_term: Retinal detachment
    term:
      id: HP:0000541
      label: Retinal detachment
- category: Ophthalmological
  name: Blindness
  description: Untreated or progressive disease can rapidly lead to irreversible blindness.
  phenotype_term:
    preferred_term: Blindness
    term:
      id: HP:0000618
      label: Blindness
  evidence:
  - reference: PMID:12768225
    reference_title: Fomivirsen.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cytomegalovirus (CMV) retinitis can rapidly lead to blindness in patients
      with acquired immune deficiency syndrome (AIDS).
    explanation: Supports blindness as the major outcome of untreated CMV retinitis.
- category: Ophthalmological
  name: Immune recovery uveitis
  description: >-
    Intraocular inflammation arising after immune reconstitution in eyes with
    prior CMV retinitis.
  phenotype_term:
    preferred_term: Uveitis
    term:
      id: HP:0000554
      label: Uveitis
  evidence:
  - reference: PMID:39046420
    reference_title: "Immune recovery uveitis: an ocular manifestation in HIV/AIDS receiving treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immune recovery uveitis is an important cause of visual morbidity
      particularly in HIV/AIDS patients receiving highly active antiretroviral.
    explanation: Supports uveitis (immune recovery uveitis) as a cause of visual morbidity after antiretroviral therapy.
treatments:
- name: Fomivirsen
  description: >-
    Fomivirsen (Vitravene) is an intravitreally administered antisense
    oligonucleotide complementary to cytomegalovirus immediate-early region 2 (IE2)
    mRNA. Approved by the FDA in 1998, it was the first antisense oligonucleotide
    drug ever approved and was used for CMV retinitis in AIDS patients, including
    relapsed disease unresponsive to conventional antivirals.
  therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE
  aso_details:
    aso_mechanism: RNASE_H_KNOCKDOWN
    target_transcript: CMV IE2 mRNA
    aso_chemistry: PHOSPHOROTHIOATE
    conjugation: UNCONJUGATED
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: fomivirsen
      term:
        id: NCIT:C174902
        label: Fomivirsen
  target_mechanisms:
  - target: Productive CMV infection of the retina
    treatment_effect: INHIBITS
    description: >-
      Antisense knockdown of CMV immediate-early region 2 (IE2) mRNA suppresses
      viral immediate-early gene expression, blocking productive replication of
      cytomegalovirus in the retina.
  target_phenotypes:
  - preferred_term: Retinitis
    term:
      id: HP:0032118
      label: Retinitis
  evidence:
  - reference: PMID:12768225
    reference_title: Fomivirsen.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fomivirsen is a novel antisense drug with a 21-nucleotide sequence
      complementary to the immediate early region 2 of CMV messenger ribonucleic
      acid.
    explanation: Establishes fomivirsen's antisense mechanism targeting CMV IE2 mRNA.
  - reference: PMID:12768225
    reference_title: Fomivirsen.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In clinical trials, fomivirsen was shown to provide effective treatment for
      newly diagnosed, peripheral CMV retinitis in patients with AIDS and in those
      with relapsed CMV retinitis that is unresponsive to conventional therapy.
    explanation: Supports clinical efficacy of fomivirsen for newly diagnosed and relapsed CMV retinitis.
  - reference: PMID:38914784
    reference_title: Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "fomiversen (for opportunistic cytomegalovirus infection)"
    explanation: Lists fomivirsen among FDA-approved antisense oligonucleotide drugs, for opportunistic CMV infection.
- name: Intravitreal ganciclovir
  description: >-
    Intravitreal ganciclovir delivers high local antiviral drug concentrations to
    control CMV retinitis, used alone or combined with systemic antiviral therapy.
  treatment_term:
    preferred_term: antiviral agent therapy
    term:
      id: NCIT:C16119
      label: Antiviral Therapy
    therapeutic_agent:
    - preferred_term: ganciclovir
      term:
        id: CHEBI:465284
        label: ganciclovir
  target_mechanisms:
  - target: Productive CMV infection of the retina
    treatment_effect: INHIBITS
    description: >-
      Ganciclovir inhibits CMV DNA polymerase, suppressing productive viral
      replication in the retina; intravitreal delivery achieves high local
      antiviral concentrations.
  target_phenotypes:
  - preferred_term: Retinitis
    term:
      id: HP:0032118
      label: Retinitis
  evidence:
  - reference: PMID:37452370
    reference_title: Comparison of two different intravitreal treatment regimens combined with systemic antiviral therapy for cytomegalovirus retinitis in patients with AIDS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To compare the efficacy and injection frequency of intravitreal low-dose vs.
      intermediate-dose ganciclovir therapy in acquired immune deficiency syndrome
      (AIDS) patients exhibiting cytomegalovirus retinitis (CMVR).
    explanation: Supports intravitreal ganciclovir as a treatment for CMV retinitis in AIDS patients.
- name: Oral valganciclovir
  description: >-
    Oral valganciclovir is a prodrug of ganciclovir providing systemic anti-CMV
    therapy for induction and maintenance treatment of CMV retinitis.
  treatment_term:
    preferred_term: antiviral agent therapy
    term:
      id: NCIT:C16119
      label: Antiviral Therapy
    therapeutic_agent:
    - preferred_term: valganciclovir
      term:
        id: CHEBI:63635
        label: valganciclovir
  target_mechanisms:
  - target: Productive CMV infection of the retina
    treatment_effect: INHIBITS
    description: >-
      Valganciclovir is an oral prodrug of ganciclovir that provides systemic
      inhibition of CMV DNA polymerase, suppressing productive viral replication
      for induction and maintenance therapy.
  target_phenotypes:
  - preferred_term: Retinitis
    term:
      id: HP:0032118
      label: Retinitis
  evidence:
  - reference: NCIT:C2629
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Valganciclovir | Accepted_Therapeutic_Use_For | - | - | Cytomegalovirus retinitis"
    explanation: >-
      NCI Thesaurus asserts accepted therapeutic use of valganciclovir for
      cytomegalovirus retinitis.
- name: Foscarnet
  description: >-
    Foscarnet is a pyrophosphate analogue antiviral used for CMV retinitis,
    particularly in ganciclovir-resistant disease or when ganciclovir is not
    tolerated.
  treatment_term:
    preferred_term: antiviral agent therapy
    term:
      id: NCIT:C16119
      label: Antiviral Therapy
    therapeutic_agent:
    - preferred_term: foscarnet
      term:
        id: NCIT:C71630
        label: Foscarnet
  target_mechanisms:
  - target: Productive CMV infection of the retina
    treatment_effect: INHIBITS
    description: >-
      Foscarnet, a pyrophosphate analogue, directly inhibits the CMV DNA
      polymerase pyrophosphate-binding site, suppressing productive viral
      replication including in ganciclovir-resistant disease.
  target_phenotypes:
  - preferred_term: Retinitis
    term:
      id: HP:0032118
      label: Retinitis
- name: Antiretroviral therapy for immune reconstitution
  description: >-
    In HIV/AIDS-associated CMV retinitis, antiretroviral therapy restores CD4+
    T-cell-mediated immunity and is essential for durable control of the underlying
    opportunistic infection, though it can precipitate immune recovery uveitis.
  treatment_term:
    preferred_term: antiretroviral therapy
    term:
      id: NCIT:C94631
      label: Antiretroviral Therapy
  target_mechanisms:
  - target: CMV reactivation under impaired cellular immunity
    treatment_effect: RESTORES
    description: >-
      Antiretroviral therapy restores CD4+ T-cell-mediated immunity, reversing
      the immunodeficiency that permits latent cytomegalovirus to reactivate and
      cause end-organ retinal disease.
  evidence:
  - reference: PMID:39046420
    reference_title: "Immune recovery uveitis: an ocular manifestation in HIV/AIDS receiving treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immune recovery uveitis is an important cause of visual morbidity
      particularly in HIV/AIDS patients receiving highly active antiretroviral.
    explanation: Supports antiretroviral therapy as the immune-reconstituting treatment context for HIV/AIDS CMV retinitis.
- name: Cidofovir
  description: >-
    Cidofovir (Vistide) is an intravenous nucleotide analogue antiviral approved
    by the FDA for CMV retinitis in AIDS patients, particularly for relapsing or
    ganciclovir-resistant disease. Its prolonged intracellular half-life allows
    biweekly maintenance dosing. Must be co-administered with oral probenecid and
    intravenous saline hydration to minimize nephrotoxicity.
  treatment_term:
    preferred_term: antiviral agent therapy
    term:
      id: NCIT:C16119
      label: Antiviral Therapy
    therapeutic_agent:
    - preferred_term: cidofovir
      term:
        id: NCIT:C1600
        label: Cidofovir
  target_mechanisms:
  - target: Productive CMV infection of the retina
    treatment_effect: INHIBITS
    description: >-
      Cidofovir, a nucleotide analogue, inhibits CMV DNA polymerase and
      suppresses productive viral replication; its prolonged intracellular
      half-life supports biweekly maintenance dosing.
  target_phenotypes:
  - preferred_term: Retinitis
    term:
      id: HP:0032118
      label: Retinitis
  evidence:
  - reference: PMID:9036797
    reference_title: >-
      Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients
      with AIDS. A randomized, controlled trial.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cidofovir was efficacious in delaying progression of previously untreated CMV retinitis."
    explanation: >-
      Randomized controlled trial demonstrating cidofovir efficacy for
      previously untreated peripheral CMV retinitis in AIDS patients.
diagnosis:
- name: CD4+ lymphocyte count and CMV risk stratification
  description: >-
    CMV retinitis occurs almost exclusively in patients with severely impaired
    cellular immunity. CD4+ lymphocyte count below 50 cells/mm³ is the principal
    immunological threshold identifying patients at highest risk for CMV end-organ
    disease; other concurrent opportunistic infections are also a risk marker.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:11294581
    reference_title: >-
      Laboratory diagnosis of cytomegalovirus (CMV) infections in
      immunodepressed patients, mainly in patients with AIDS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      appears almost exclusively in patients with a CD4+ lymphocyte count lower
      than 50/mm3 and when other opportunistic infections have occurred.
    explanation: >-
      Establishes CD4+ count below 50/mm³ as the key risk threshold identifying
      HIV-positive patients at highest risk for CMV end-organ disease.
- name: CMV viral load quantification (pp65 antigenemia and quantitative PCR)
  description: >-
    Active CMV infection is confirmed and monitored by quantitative viral load
    methods, primarily pp65 antigenemia and quantitative PCR. These assays
    identify patients with high viral burden at risk of progressing to CMV
    disease and guide pre-emptive antiviral treatment. Shell-vial rapid culture
    is an alternative for rapid diagnosis of active infection.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:11294581
    reference_title: >-
      Laboratory diagnosis of cytomegalovirus (CMV) infections in
      immunodepressed patients, mainly in patients with AIDS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Techniques allowing the quantification of CMV viremia, namely pp65
      antigenemia and quantitative PCR, have been most useful to this end.
    explanation: >-
      Supports pp65 antigenemia and quantitative PCR as primary methods for
      quantifying CMV viremia and identifying high-risk patients for
      pre-emptive antiviral therapy.
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0000878
      label: cytomegalovirus retinitis
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: MONDO provides an exact disease term for cytomegalovirus retinitis.
  ncit_mappings:
  - term:
      id: NCIT:C50521
      label: Cytomegaloviral Retinitis
    mapping_predicate: skos:exactMatch
    mapping_source: NCIT
    mapping_justification: NCIT provides an exact term for cytomegalovirus retinitis; cross-referenced from MONDO:0000878.